CARDISTM Platform – Discover and optimize ScFv-based CARs to surface-expressed antigens

  • Hybrid of phage & proprietary mammalian display platforms

  • Direct functional selection from pooled library – more & better hits

  • Fully human ScFv libraries – lower risk of immunogenicity

T Cell Receptor (TCR) therapies represent the next generation opportunity to empower immune effector cells for ACT. TCRs recognize components of tumor-specific proteins from inside of cells in a different way than antibodies and, therefore, require precise characterization and, in many cases, engineering. ACTs utilizing TCRs widen the scope of tumor targets beyond CAR-based approaches, and in addition, TCR and CAR ACT approaches offer complementary ways to treat cancer.


T-RxTM Platform – Discover and optimize TCRs to intracellular antigens

  • Based on proprietary mammalian display platform

  • Direct functional selection from pooled library – more & better hits

  • TCRs from natural donors – leverage natural thymic selection

  • De novo TCR discovery – any HLA, any presented peptide

  • Extensive proprietary off-target profiling